GBS-NN/NN2 vaccine

BIOLOGICAL3 trials

Sponsors

Minervax ApS

Conditions

Bacterial InfectionsBacterial Infections and MycosesGram-Positive Bacterial InfectionsGroup B Streptococcal InfectionInfectionsMeningitisNeonatal InfectionNeonatal Sepsis

Phase 2

Immunogenicity and Safety of GBS-NN/NN2 in Pregnant Women

CompletedNCT05154578

Minervax ApSGroup B Streptococcal Infection

Start: 2022-02-17End: 2023-10-18Updated: 2025-06-11

GBS-NN/NN2 (50 µg of Each Fusion Protein [GBS-NN and GBS-NN2] in Combination With 500 µg Aluminum as Alhydrogel®) Given With and Without the Tdap Vaccine in Healthy Non-pregnant Women 18 to 49 Years of Age

Not yet recruitingNCT06494475

Minervax ApSStreptococcus Agalactiae Infection

Start: 2024-12-17End: 2025-06-21Target: 564Updated: 2024-07-10

A Follow-up Trial of GBS-NN/NN2 Vaccine in Healthy Pregnant Women

Active, not recruitingNCT06592586

Minervax ApSBacterial Infections, Bacterial Infections and Mycoses, Gram-Positive Bacterial Infections +6

Start: 2025-03-07End: 2029-06-30Updated: 2026-09-04

Related Papers

Immunogenicity and safety of a group B Streptococcus vaccine (GBS-AlpN) in pregnant women and their infants: a phase 2, multicentre, observer-blind, randomised, placebo-controlled study.

2025-12-09